Bracco Imaging has secured clearance from the European Commission for the use of its contrast agent Vueway in pediatric patients under the age of 2.
Vueway (gadopiclenol) is a novel macrocyclic gadolinium-based contrast agent (GBCA) approved in 36 countries and used in MRI exams to help doctors find certain pathologies in patients.
The product was approved in Europe in December 2023 for use in adults and children over 2 years old to improve the detection and visualization of pathologies with disruption of the blood-brain-barrier and/or abnormal vascularity of the brain, spine, and associated tissues of the central nervous system, as well as in contrast-enhanced MRI of the liver, kidney, pancreas, breast, lung, prostate, and musculoskeletal system, Bracco noted.
Large, multicenter clinical studies have shown that Vueway delivers comparable diagnostic efficacy at half the gadolinium dose of gadobutrol, a GBCA widely used in clinical practice across the world, according to the firm.
